Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 1;36(1):15-19.
doi: 10.1097/QCO.0000000000000896.

Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus

Natalie E Lee  1 , Rebecca K Sutherland
Affiliations
Review

Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus

Natalie E Lee et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: The aim of this study was to summarize current evidence regarding lenacapavir, a first in class HIV-1 capsid inhibitor, and its role as an emergent therapy for the treatment of HIV-1 infection.

Recent findings: HIV-1 capsid inhibitors (of which lenacapavir is the first in class) has been postulated to have activity against multidrug resistant HIV-1 viral isolates. Initial results from the phase 3 trial CAPELLA (combining oral and subcutaneous lenacapavir alongside failing drug therapies) suggest that there may be a role for these novel agents in a cohort of patients living with HIV-1 infection (PLWH) for whom multidrug resistance has previously been a barrier to effective therapy. Despite emergent lenacapavir resistance mutations detected in some study participants, virological suppression was still potentially attainable, offering some hope to PLWH with limited antiviral regimens available. Initial results from the CALIBRATE trial show promise for the role of lenacapavir-containing regimens in a treatment-naive cohort as well.

Summary: Lenacapavir may prove to be an adjunctive agent in the management of PLWH with significant HIV-1 drug resistance.

PubMed Disclaimer

References

    1. Overton E, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, noninferiority study. Lancet 2021; 396:1994–2005.
    1. HIV drug resistance report 2021 WHO publication 24 Nov 2021.
    1. Lawn SD, Little F, Bekker L-G, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335–342.
    1. Spearman P. HIV-1 Gag as an antiviral target: development of assembly and maturation inhibitors. Curr Top Med Chem 2016; 16:1154–1166.
    1. Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med 2022; 386:1793–1803.

Substances